Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
Ad hoc announcements pursuant to Art. 53 LR
Baar, Switzerland, 16 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive interim result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).
[…]